Protara Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.
“and for the full year increased to $42.6 million compared to $31.7 million for 2024”
Earnings Releases
Quarterly and annual results disclosed under 8-K Item 2.02.
Protara Therapeutics, Inc. reported financial results for the fourth quarter of 2025.
“Research and development expenses for the fourth quarter of 2025 increased to $13.1 million from $9.5 million for the prior year period”
AeroVironment Inc reported fiscal year 2026 results: revenue $1.85 billion and $1.95 billion, net income $(218) million and $(201) million, EPS $(4.44) and $(4.10) per diluted share.
“For fiscal year 2026, the Company now expects revenue of between $1.85 billion and $1.95 billion, net loss of between $(218) million and $(201) million, non-GAAP adjusted EBITDA of between $265 million and $285 million, loss per diluted share of between $(4.44) and $(4.10) and non-GAAP earnings per diluted share, which excludes amortization of intangible assets, other non-cash purchase accounting expenses, goodwill impairment, equity securities investments gains or losses, and equity method income or loss of between $2.75 and $3.10.”
AeroVironment Inc reported the fiscal third quarter ended January 31, 2026 results: revenue $408.0 million, net income $(156.6) million, EPS $(3.15) per diluted share.
“(“AeroVironment” or the “Company”) reported today financial results for the fiscal third quarter ended January 31, 2026. Third Quarter Highlights: ● Third quarter revenue of $408.0 million ● Bookings of $2.1 billion and book-to-bill ratio of 1.6 for the first nine months of the fiscal year ● Record funded backlog of $1.1 billion “While our third quarter results”
Esperion Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $403.1 Million.
“– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –”
Esperion Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $168.4 Million.
“– Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million –”
Groupon, Inc. reported financial results for the quarter and year ended December 31, 2025.
“On March 10, 2026 , Groupon, Inc. (the "Company") issued a press release announcing its financial results for its fiscal quarter ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.”
Global Indemnity Group, LLC reported the twelve months ended December 31, 2025 results: net income $24.9 million, EPS $1.75 per diluted share.
“Net income available to common shareholders was $24.9 million, or $1.75 per diluted share”
DOMO, INC. reported financial results for fiscal quarter and year ended January 31, 2026.
“On March 10, 2026, Domo, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter and year ended January 31, 2026 and certain other information. The full text of the press release is set forth in Exhibit 99.1 hereto and incorporated by reference herein.”
Nuwellis, Inc. reported the full year ended December 31, 2025 results: revenue $8.3 million, net income $17.5 million.
“Revenue for the full year ended December 31, 2025, was $8.3 million, a 5% decrease compared to the prior year.”
Nuwellis, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.4 million, net income approximately $2.4 million.
“conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: • Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially. • 208% increase in U.S. console sales in Q4 versus prior year quarter. • Heart Failure revenue”
Ideal Power Inc. reported the year ended December 31, 2025 results: net income $10.6 million.
“Net loss in the full year 2025 was $10.6 million compared to $10.4 million in the full year 2024.”
Ideal Power Inc. reported the fourth quarter ended December 31, 2025 results: net income $1.9 million.
“Net loss in the fourth quarter of 2025 was $1.9 million compared to $2.6 million in the fourth quarter of 2024.”
SURO CAPITAL CORP. updated its the fiscal year ended December 31, 2025 guidance (initiated).
“Net assets totaled approximately $205.3 million, or $8.09 per share, at December 31, 2025”
SURO CAPITAL CORP. reported the fourth quarter ended December 31, 2025 results: net income $ (20.1 ), EPS $ (0.79 ). Guidance initiated.
“Quarter Ended December 31, 2025 Quarter Ended December 31, 2024 $ in millions per share (1) $ in millions per share (1) Net investment loss $ (5.7 ) $ (0.22 ) $ (3.9 ) $ (0.16 ) Net realized gain on investments 6.8 0.27 9.1 0.39 Realized loss on partial repurchase of 6.00% Notes due 2026 (<0.1 ) (<0.01 ) (<0.1 ) (<0.01 ) Net change in unrealized depreciation of investments (21.3 ) (0.84 ) (5.2 ) (0.22 ) Net increase/(decrease) in net assets resulting from operations– basic (2) (20.1 ) (0.79 ) <0.1 <0.01”
Arq, Inc. reported the fiscal year ended December 31, 2025 results: revenue $120.3 million, net income Net loss of $52.6 million. Guidance initiated.
“• Generated revenue of $120.3 million in FY 2025 ($29.4 million in Q4 2025), up 10% over the prior year, driven largely by positive changes in product mix and overall volumes • Gross margin of 27.9% in FY 2025 vs. 36.2% in FY 2024, driven by higher costs directly related to granular activated carbon (“GAC”) start-up costs • Gross margin in Q4 2025 of 13.6% vs. 36.3% in Q4 2024, reflecting negative impact of GAC start-up costs • Recorded non-cash impairment charge of $45 million related to Corbin assets in Q4 2025, reflecting the temporary idling of the Corbin facility. • Reported Net loss of $52.6 million in FY 2025, versus a Net loss of $5.1 million in FY 2024”
Arq, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $29.4 million, net income Net loss of $50.0 million. Guidance initiated.
“• Generated revenue of $120.3 million in FY 2025 ($29.4 million in Q4 2025), up 10% over the prior year, driven largely by positive changes in product mix and overall volumes • Gross margin of 27.9% in FY 2025 vs. 36.2% in FY 2024, driven by higher costs directly related to granular activated carbon (“GAC”) start-up costs • Gross margin in Q4 2025 of 13.6% vs. 36.3% in Q4 2024, reflecting negative impact of GAC start-up costs • Recorded non-cash impairment charge of $45 million related to Corbin assets in Q4 2025, reflecting the temporary idling of the Corbin facility. • Reported Net loss of $52.6 million in FY 2025, versus a Net loss of $5.1 million in FY 2024; Q4 2025 Net loss of $50.0 million vs. Net loss of $1.3 million in Q4 2024”
Skye Bioscience, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 10, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2025.”
Lipocine Inc. reported the full year ended December 31, 2025 results: revenue $2.0 million, net income net loss of $9.6 million, EPS ($1.69) per diluted share.
“per diluted share, for the year ended December 31, 2025, compared with net income of $8,352, or ($0.00) per diluted share, for the year ended December 31, 2024. Revenues were $2.0 million during the year ended December 31, 2025, compared to revenue of $11.2 million during the year ended December 31, 2024. Revenue in 2025 primarily consisted of license revenue from”
Virtuix Holdings Inc. reported the three months ended December 31, 2025 results: revenue $1.0 million.
“Net sales for the three months ended December 31, 2025 were $1.0 million, compared to $1.3 million in the prior year period.”
Virtuix Holdings Inc. reported the nine months ended December 31, 2025 results: revenue $3.0 million.
“Net sales for the nine months ended December 31, 2025 were $3.0 million, an increase of $0.9 million or 41% from net sales of $2.1 million for the prior year period.”
Inspired Entertainment, Inc. updated its fourth quarter and fiscal year ended December 31, 2025 guidance (reaffirmed).
“On March 10, 2026, Inspired Entertainment, Inc. (the “Company”) issued a press release announcing results for the fiscal year ended December 31, 2025 and the three-month period ended December 31, 2025.”
Barnes & Noble Education, Inc. reported first nine months of fiscal 2026 results: revenue $1,447.7 million, net income $13.4 million.
“Revenue for the first nine months of fiscal 2026 was $1,447.7 million”
Barnes & Noble Education, Inc. reported fiscal third quarter ended January 31, 2026 results: revenue $515.1 million, net income $6.7 million.
“details, including registration information, will be provided in the coming weeks. Fiscal Third Quarter 2026 Financial Results Revenue for the fiscal third quarter of 2026 was $515.1 million, an increase of 11.3% compared to $462.8 million for the third quarter of fiscal 2025. Gross Comparable Store Sales increased by $33.8 million, or 7.2%, year-over-year. Revenues”
vTv Therapeutics Inc. reported financial results for the full year ended December 31, 2025.
“vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments.”
vTv Therapeutics Inc. reported the fourth quarter ended December 31, 2025 results: net income $7.1 million, EPS $0.58 per basic share.
“Net loss attributable to vTv shareholders for the three months ended December 31, 2025, was $7.1 million or $0.58 per basic share.”
Priority Technology Holdings, Inc. reported Full Year 2025 results: revenue $953.0 million.
“Full Year 2025 Compared with Full Year 2024 Financial highlights of the Full Year of 2025 compared with the Full Year of 2024, are as follows (2) : • Revenue of $953.0 million increased 8.3% from $879.7 million, including 7.7% in organic growth”
Priority Technology Holdings, Inc. reported the quarter ended December 31, 2025 results: revenue $247.1 million.
“Quarter 2025 Compared with Fourth Quarter 2024 Financial highlights of the fourth quarter of 2025 compared with the fourth quarter of 2024, are as follows 2 : • Revenue of $247.1 million increased 8.8% from $227.1 million, including 6.8% of organic growth • Adjusted gross profit (a non-GAAP measure 1 ) of $100.2 million increased 19.4% from $83.9 million •”
Q32 Bio Inc. reported financial results for quarter ended December 31, 2025.
“Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended December 31, 2025, and provided recent corporate updates.”
SS Innovations International, Inc. reported the twelve months ended December 31, 2025 results: revenue $42.5 million, net income $12.1 million, EPS $(0.06) per diluted share.
“Full Year 2025 Overview ● Revenue increased 105.7% to $42.5 million from $20.6 million in 2024. ● Gross margin expanded to 46.0% from 40.9% in 2024. ● Gross profit rose 131.2% to $19.5 million from $8.5 million in 2024. ● Net loss of $12.1 million, or $(0.06) per diluted share, compared to net loss of $19.2 million, or $(0.11) per diluted share, in 2024.”
SS Innovations International, Inc. reported the three months ended December 31, 2025 results: revenue $14.5 million, net income $2.5 million, EPS $(0.01) per diluted share.
“Fourth Quarter 2025 Overview ● Revenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024. ● Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024. ● Gross profit rose 60.7% to $6.4 million from $4.0 million in the fourth quarter of 2024. ● Net loss of $2.5 million, or $(0.01) per diluted share, compared to a net loss of $1.9 million, or $(0.01) per diluted share, in the fourth quarter of 2024.”
Prelude Therapeutics Inc reported financial results for the full year ended December 31, 2025.
“Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the full year ended December 31, 2025”
SHOULDER INNOVATIONS, INC. updated its fourth quarter and year ended December 31, 2025 guidance (initiated).
“On March 10, 2026, Shoulder Innovations, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025.”
Concrete Pumping Holdings, Inc. reported first quarter of fiscal year 2026 results: revenue $90.6 million, net income $2.9 million, EPS $(0.06) per diluted share.
“Revenue up 5% to $90.6 million compared to $86.4 million.”
Custom Truck One Source, Inc. reported fiscal year ended December 31, 2025 results: revenue $1,944.0 million, net income $31.1 million net loss.
“• Record fourth quarter revenue of $528.2 million, an increase of $7.4 million or 1.4%, compared to the fourth quarter of 2024 • Record full-year revenue of $1,944.0 million, an increase of 7.9%, compared to 2024 • Quarterly net income of $20.9 million, compared to net income of $27.6 million for the fourth quarter of 2024 • Full-year net loss of $31.1 million compared to a net loss of $28.7 million in 2024”
Custom Truck One Source, Inc. reported fourth quarter ended December 31, 2025 results: revenue $528.2 million, net income $20.9 million.
“• Record fourth quarter revenue of $528.2 million, an increase of $7.4 million or 1.4%, compared to the fourth quarter of 2024 • Record full-year revenue of $1,944.0 million, an increase of 7.9%, compared to 2024 • Quarterly net income of $20.9 million, compared to net income of $27.6 million for the fourth quarter of 2024 • Full-year net loss of $31.1 million compared to a net loss of $28.7 million in 2024”
ADC Therapeutics SA reported financial results for the fourth quarter and year ended December 31, 2025.
“On March 10, 2026, ADC Therapeutics SA (the "Company") issued a press release announcing the Company's financial results for the fourth quarter and year ended December 31, 2025.”
Cullinan Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to Cullinan was $50.7 million for the fourth quarter of 2025, compared to $47.6 million for the sa.
“On March 10, 2026, Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the year ended December 31, 2025.”
Xponential Fitness, Inc. updated its full-year 2026 guidance (reaffirmed).
“Today, Xponential reaffirmed its full-year 2026 financial guidance, as previously announced in the fourth quarter and full-year 2025 earnings release issued on February 26, 2026.”
Evolv Technologies Holdings, Inc. reported 2026 results: revenue between $172 to $178 million. Guidance raised.
“The Company expects total revenues in 2026 to be between $172 to $178 million, reflecting growth of approximately 18% to 22% year-over-year.”
Evolv Technologies Holdings, Inc. reported the twelve months ended December 31, 2025 results: revenue $145.9 million, net income $(33.1) million, EPS $(0.20) per basic and diluted share.
“Total revenue for the twelve months ended December 31, 2025 was $145.9 million, an increase of 40% compared to $103.9 million for the twelve months ended December 31, 2024. Net loss for the twelve months ended December 31, 2025 was $(33.1) million, or $(0.20) per basic and diluted share, compared to $(54.0) million, or $(0.34) per basic and diluted share, in the twelve months ended December 31, 2024.”
Evolv Technologies Holdings, Inc. reported the fourth quarter of 2025 results: revenue $38.5 million, net income $10.9 million, EPS $0.06 per diluted share.
“Total revenue for the fourth quarter of 2025 was $38.5 million, an increase of 32% compared to $29.1 million for the fourth quarter of 2024. Revenue for the fourth quarter of 2025 was primarily driven by strong new customer additions and continued expansion of deployments across the existing customer base. Annual Recurring Revenue (“ARR”) 1 was $120.5 million at the end of fourth quarter of 2025, an increase of 21% compared to $99.4 million at the end of the fourth quarter of 2024. Net income for the fourth quarter of 2025 was $10.9 million, or $0.06 per basic share and $0.06 per diluted share, compared to net loss of $(15.7) million, or $(0.10) per basic and diluted share, in the fourth quarter of 2024.”
Westrock Coffee Co reported fourth quarter ended December 31, 2025 results: revenue Net sales were $339.5 million.
“Net sales were $339.5 million, an increase of 48.3% o Gross profit was $38.9 million, an increase of 2.3%”
Westrock Coffee Co reported full year ended December 31, 2025 results: revenue Net sales were $1.2 billion, net income Net loss was $90.4 million.
“Consolidated Results o Net sales were $1.2 billion, an increase of 39.8% o Gross profit was $150.8 million, a decrease of 2.0% o Net loss was $90.4 million, compared to a net loss of $80.3 million in the prior year period”
Artiva Biotherapeutics, Inc. reported the year ended December 31, 2025 results: revenue zero, net income Net loss totaled $83.9 million.
“On March 10, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the year ended December 31, 2025.”
Motorsport Games Inc. reported fiscal year ended December 31, 2025 results: revenue $11.3 million, net income $6.8 million, EPS $1.43 per share.
“Revenues for the full year 2025 were $11.3 million compared to $8.7 million for the prior year, an increase of $2.6 million, or 30.0%. Gaming segment revenues represented 100% of the Company’s total 2025 and 2024 revenues, The increase in Gaming segment revenues was primarily due to a $5.8 million increase in 2025 from sales of our Le Mans Ultimate racing title released in February 2024, particularly DLC sales, which were higher compared to 2024, and $1.2 million from RaceControl, offset by a $4.4 million decrease in revenues in 2025 related to NASCAR, a gaming title the company decided to sell so that we might concentrate our efforts elsewhere. As a result, we were not selling the NASCAR titles from the start of 2025. We did not organize a Le Mans Virtual Series event in 2025 or 2024, resulting in no earned sponsorship or events revenue in 2025 and 2024 in our Esports segment. Consolidated gross profit was $9.2 million for the full year 2025 compared to $5.5 million for the prior year”
Motorsport Games Inc. reported the fourth quarter of 2025 results: revenue $3.8 million, net income $0.8 million, EPS $0.15 per share.
“Revenue for the fourth quarter of 2025 was $3.8 million compared to $2.0 million for the same period in the prior year, an increase of $1.8 million, or 94.9%. Gross profit was $3.3 million compared to $0.9 million for the same period in the prior year, an increase of $2.4 million, while gross profit margin increased to 85.0% from 45.8%. Net income for the fourth quarter of 2025 was $0.8 million, compared to net loss $2.9 million for the same period in the prior year, an increase of $3.7 million. The increase in net income is driven by an increase in sales of our Le Mans Ultimate racing title, particularly downloadable content (“DLC”) sales. Consequently, net income attributable to Class A common stock was $0.15 per share for the fourth quarter of 2025, compared to net loss per share of $0.89 in the same prior year period.”
Beachbody Company, Inc. reported the first quarter of 2026 results: revenue $49 to $54 million, net income $ (2) to $ 1 million. Guidance initiated.
“Outlook for The First Quarter of 2026 Outlook For Quarter Ending March 31, 2026 (in millions) Low High Revenue $ 49 $ 54 Net Income (Loss) (1) $ (2 ) $ 1”
Beachbody Company, Inc. reported the year ended December 31, 2025 results: revenue $251.7 million, net income ($2.9 million).
“year period. • Adjusted net income (loss) 1 was income of $7.2 million compared to a loss of $4.7 million in the prior year period. Full Year 2025 Results • Total revenue was $251.7 million compared to $418.8 million in the prior year. o Digital revenue was $153.3 million compared to $224.3 million in the prior year. o Nutrition and Other revenue was $97.6 million”
Beachbody Company, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $55.5 million, net income $5.2 million.
“and financial flexibility to capitalize on a massive market opportunity that represents the next phase of our growth strategy.” Fourth Quarter 2025 Results • Total revenue was $55.5 million compared to $86.4 million in the prior year period. o Digital revenue was $34.3 million compared to $50.4 million in the prior year period and digital subscriptions totaled 0.87”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.